SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's Groundbreaking DiversitAb™ Platform
- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application for Company’s antibody generating DiversitAb™ platform in... | May 9, 2023
Eddiej Sullivan Alexandra Kropotova Exchange Commission Biotherapeutics Inc Drug Administration National Institutes Of Health
Source: marketscreener.com